Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIALYSIS-TIR: Semaglutide for Dialysis-Treated Patients
NCT06042153Phase 4Active, not recruiting
- Sponsor
- UT Southwestern Medical Center
- Start
- Dec 2023
- Primary completion
- Sep 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Arm 1 - Semaglutide with Arm 2- Placebo (2 arms). Primary endpoint: Change in Time in Range (70-180 mg/dl) at 52 weeks. Started Dec 2023; status: active, not recruiting.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06042153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06042153.